Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

asciminib

Novartis building

Scientists finds new drug target for malaria

Novartis and academics identify new class of medicines to treat all stages of infection

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

Roche - Basel

EU backs Roche’s Kadcyla in breast cancer

Green light for Herceptin follow-up

Bayer symbol

EU approval for Bayer’s prostate cancer drug

Xofigo wins marketing authorisation from European Commission

Novartis building

Novartis offloads diagnostics unit to Grifols for $1.7bn

Part of strategy to focus on more profitable businesses

- PMLiVE

Novartis debates future of Horsham site

UK research centre could close

Novartis building

Novartis weighs in on biosimilar naming debate

Files petition urging FDA to keep system where biosimilars share a name with the original drug

- PMLiVE

Late-stage ovarian cancer

Novel treatment strategies have yielded several promising agents that have reached phase III

- PMLiVE

Novartis’ Lucentis wins fourth NICE recommendation

But eye drug only recommended after a price-cutting patient access scheme offered

- PMLiVE

Priority review for Lilly’s ramucirumab in gastric cancer

Update comes as company posts improved revenue results

Novartis building

NICE backs Novartis/ ThromboGenics’ eye drug

Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links